Key facts
- Convoke (Business/Productivity Software)’s last known valuation is $36.0M (Jul 2024).
- It has raised $17.1M; the latest was Seed Round ($8.6M) in Aug 2025.
- Notable investors include Liquid 2 Ventures, Lux Capital, Kleiner Perkins, ACME Capital, Not Boring — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Convoke (Business/Productivity Software)
- ·The full record, as it builds
Funding rounds
No funding rounds for Convoke (Business/Productivity Software) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Convoke (Business/Productivity Software)
Developer of a biotechnology research software designed to help increase the capital efficiency of the biopharmaceutical industry. The company specializes in curating high-quality datasets, automating workflows, and offering a software platform, enabling drug developers to plan for the clinical development, launch, and commercialization of pharmaceutical products.
- Sector
- Information Technology
- HQ
- Palo Alto, CA, United States
- Founded
- 2024
- Employees
- 2
- Website
- convoke.bio/
- Ownership
- Privately Held (backing)
Convoke (Business/Productivity Software) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Convoke (Business/Productivity Software) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Convoke (Business/Productivity Software) in its N-PORT filings yet. We sweep new filings monthly.